Anixa Biosciences Inc

Anixa Biosciences Inc (ANIX) is a publicly listed company on US equity markets.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

The company reports trailing twelve-month revenue of $210,000 and net loss of $2.56M.

Key metrics include a return on equity of -17.0%, a debt-to-equity ratio of 0.09.

Use FINOTAUR to track ANIX's price action, review fundamentals, and stay current with company news — all in one research dashboard.